Unpacking FDA's MDMA rejection letter and the road ahead for Lykos

FDA's MDMA decision is framed as a key regulatory inflection point for Lykos and for the broader push to bring MDMA-assisted therapy into mainstream clinical use. The piece unpacks what the rejection letter likely turns on in regulatory terms, emphasizing how agency concerns shape what evidence, study design, and trial execution a sponsor must deliver next. It connects the letter to practical next steps, including what changes would be needed to address the FDA's stated issues. The broader implication is that the path forward for MDMA-assisted therapy depends not only on scientific rationale but also on navigating regulatory standards and demonstrating reproducible safety and efficacy at the level required for approval.